Clinical Trial Update: Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"

View source ↗

Summary

A long-term use survey of Leuprorelin Acetate SR 11.25 mg for injection in premenopausal breast cancer patients (96 weeks) completed with results posted in 2016…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Leuprorelin Acetate SR 11.25 mg for Injection (leuprorelin acetate)

Snippet

Sponsor: Takeda | Conditions: Breast Cancer | Status: COMPLETED | Results posted: 2016-02-17